Michael E Wyrick, PHD | |
1420 Longview Dr, Booneville, AR 72927-3830 | |
(479) 675-6392 | |
Not Available |
Full Name | Michael E Wyrick |
---|---|
Gender | Male |
Speciality | Psychologist - Cognitive & Behavioral |
Location | 1420 Longview Dr, Booneville, Arkansas |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1679074082 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103TB0200X | Psychologist - Cognitive & Behavioral | 80-15P (Arkansas) | Primary |
Mailing Address | Practice Location Address |
---|---|
Michael E Wyrick, PHD 1420 Longview Dr, Booneville, AR 72927-3830 Ph: (479) 675-6392 | Michael E Wyrick, PHD 1420 Longview Dr, Booneville, AR 72927-3830 Ph: (479) 675-6392 |
News Archive
In the first evidence that natural selection favors an individual's infection tolerance, researchers from Princeton University and the University of Edinburgh have found that an animal's ability to endure an internal parasite strongly influences its reproductive success.
The last year and a half have been a struggle for all of us, and that's putting it lightly. But in terms of mental health, apartment-dwelling Americans-;especially those living alone-;may have suffered more mental health problems during the COVID-19 pandemic than those living with their families in the suburbs, suggests new research from the University of Georgia.
Cohera Medical, Inc. announced today that it has received approval to begin human clinical trials of its lead product TissuGlu® in Germany. Receipt of the approval allows Cohera Medical to proceed with patient recruitment and initiation of an investigational study of the company's novel internal surgical adhesive being developed for its first intended use to adhere surgical tissues together in large flap surgeries.
Patients who are overweight or obese have more severe COVID-19 and are highly likely to require invasive respiratory support, according to a new international study.
Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.
› Verified 9 days ago